The present invention provides heterocyclic compounds which can act as protein tyrosine kinase inhibitors. Preferred embodiments include both novel and known substituted 2-aryl benzimidazole and benzofuro [3,2-c ] quinoline compounds. Methods of utilizing preferred compounds in preparation of medicaments for the treatment of proliferative, skeletal and metabolic diseases and disorders associated with abnormal protein tyrosine kinase activity, including cancer and skeletal dysplasia, are provided.
